Cardiotrition® Booster Combination Therapy for Active Cardiac Patients: Mechanisms of Action in Diabetic Comorbidity and Statin-Associated Side Effects

Arvid Jensen[1], Marianne Smith[2], Ali Saadani[3], Rahma H. Hagaggy[4]*, and Manal Ibrahim[5]

[1] Senior Technical Consultant, Scientific Department, Nanotrition Nord, Borre, Norway
[2] Technical Executive, Scientific Department, Nanotrition Nord, Borre, Norway
[3] Chief Officer, Scientific Department, Nanotrition Nord, Cairo, Egypt
[4] Research Executive Specialist, Scientific Department, Polygon Research Center, Cairo, Egypt
[5] Research Specialist, Scientific Department, Nanotrition Nord, Cairo, Egypt

Corresponding Author:
Rahma H. Hagaggy
Research Executive Specialist
Polygon Research Center
Cairo, Egypt
Email: rahma.hassan@nanotrition.tech
Tel: +20 109 471 5451

ABSTRACT

Background: Cardiovascular diseases remain the leading cause of mortality worldwide, with standard pharmacotherapy addressing hemodynamic and neurohormonal pathways but failing to restore mitochondrial function or correct bioenergetic deficits in cardiomyocytes. Cardiotrition® Booster, an advanced mitochondrial bioenergetic formulation combining INNOVA3® liposomal Coenzyme Q10 (200 mg), INNOVA3® liposomal R-alpha lipoic acid (300 mg), and acetyl-L-carnitine (500 mg), addresses this critical therapeutic gap. Beyond its primary cardiac indication, the formulation offers clinically meaningful benefits for two high-prevalence conditions in cardiovascular patients: diabetic comorbidity and statin-associated side effects.

Objective: This paper examines the evidence for Cardiotrition® Booster's components in addressing diabetic cardiomyopathy and statin-associated muscle symptoms, demonstrating that the formulation's clinical value extends well beyond its primary cardiac indications.

Methods: A comprehensive review of recent clinical evidence was conducted, focusing on randomized controlled trials and meta-analyses evaluating alpha-lipoic acid in diabetic cardiomyopathy and coenzyme Q10 in statin-associated muscle symptoms. Key outcome measures included inflammatory biomarkers (TNF-α, CRP), fibrosis markers (TGF-β1, MMP-2), echocardiographic parameters (LVEF), and muscle pain intensity scores.

Results: In a 2025-2026 randomized controlled trial of 67 diabetic patients with ischemic cardiomyopathy, adjunctive alpha-lipoic acid therapy (600 mg daily for three months) significantly reduced inflammatory markers—TNF-α [443 (326/515) vs. 499 (448/657) pg/ml], CRP [4.5 (4.2/6.1) vs. 11 (6.3/12.1) mg/l]—and fibrosis markers—TGF-β1 [161 (104/189) vs. 206 (158/248) pg/ml], MMP-2 [1450 (1164/1894) vs. 1815 (1339/2133) pg/ml] ($p < 0.05$ for all comparisons). Left ventricular ejection fraction improved significantly [36% (34/40) vs. 28% (25/31.8); $p < 0.05$]. For statin-associated muscle symptoms, a 2025 meta-analysis of seven randomized controlled trials (389 patients) demonstrated that CoQ10 supplementation significantly reduced muscle pain intensity (weighted mean difference −0.96; 95% CI −1.88 to −0.03; $p < 0.05$).

Conclusions: Cardiotrition® Booster provides synergistic benefits addressing mitochondrial dysfunction, oxidative stress, and inflammation in diabetic patients while mitigating statin-induced CoQ10 depletion. The 2.56–2.71× bioavailability enhancement and Triple-Phase Energy Cycle™ sequential activation ensure each component reaches therapeutic levels at the appropriate physiological time. These findings support Cardiotrition® Booster as an evidence-informed adjunctive strategy for active cardiac patients with diabetic comorbidity or statin-associated side effects.

Keywords: Diabetic cardiomyopathy; statin-associated muscle symptoms; Coenzyme Q10; alpha-lipoic acid; mitochondrial dysfunction; oxidative stress; cardiovascular disease; Cardiotrition® Booster; liposomal delivery; cardiac bioenergetics

1. INTRODUCTION

1.1 The Global Burden of Cardiovascular Disease and the Mitochondrial Gap

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, accounting for approximately 17.9 million deaths annually. In Egypt, CVDs represent 46% of all deaths, with 275,665 CVD-related deaths recorded in 2025. Despite remarkable advances in pharmacological and interventional therapies, the global burden of CVD continues to rise, driven by aging populations, increasing prevalence of metabolic risk factors, and the growing recognition of mitochondrial dysfunction as a central pathophysiological mechanism. Standard pharmacotherapy—including beta-blockers, ACE inhibitors, statins, and antiplatelet agents—primarily addresses hemodynamic and neurohormonal pathways but does not restore mitochondrial function or correct bioenergetic deficits in cardiomyocytes. The heart, as one of the most energy-demanding organs in the human body, requires a continuous and substantial supply of adenosine triphosphate (ATP) to maintain its contractile function and hemodynamic stability.

Mitochondrial oxidative phosphorylation generates approximately 95% of cardiac ATP, and in heart failure and post-myocardial infarction states, mitochondrial dysfunction leads to "energetic starvation"—a key driver of disease progression. The heart's enormous energy demand renders it exceptionally vulnerable to disruptions in mitochondrial bioenergetics, including impaired electron transport chain function, excessive reactive oxygen species (ROS) generation, and reduced ATP availability. This "mitochondrial gap" leaves even optimally treated patients suffering from persistent fatigue, dyspnea, reduced exercise tolerance, and impaired quality of life.

1.2 The Role of Mitochondrial Dysfunction in Cardiac Disease

Mitochondrial bioenergetic dysfunction is increasingly recognized as a central determinant of systemic fatigue, subclinical cardiac impairment, and early cardiometabolic decline. The pathological remodeling observed in heart failure stems from multifaceted disruptions in cardiac energy metabolism, primarily involving mitochondrial dysfunction, dysregulated substrate control, aberrant transcriptional regulation, and post-translational modifications. Mitochondrial dysfunction manifests as impaired transcriptional control of mitochondrial biogenesis, excessive reactive oxygen species (ROS) production, and disturbances in mitochondrial dynamics including fission, fusion, and mitophagy. Common risk factors for developing heart failure—including hypertension, obesity, diabetes, coronary heart disease, and inflammation—are all associated with mitochondrial dysfunction.

At the molecular level, reduced availability and recycling efficiency of electron carriers—most notably coenzyme Q10 (ubiquinone)—lead to impaired electron flux through complexes I–III of the mitochondrial respiratory chain. This inefficiency is compounded by limitations in fatty acid transport into mitochondria, primarily governed by L-carnitine-dependent shuttling mechanisms, resulting in suboptimal substrate utilization. Concurrently, oxidative stress driven by mitochondrial ROS overproduction further disrupts membrane integrity, enzymatic activity, and mitochondrial DNA stability, establishing a self-amplifying cycle of bioenergetic decline.

1.3 The Cardiotrition® Booster Formulation: A Multi-Targeted Approach

Cardiotrition® Booster was developed as an advanced mitochondrial bioenergetic formulation integrating three key components:

1. INNOVA3® Liposomal Coenzyme Q10 (200 mg) – CoQ10 is an indispensable component of the mitochondrial electron transport chain and plays a central role in ATP synthesis while acting as a potent lipid-soluble antioxidant. INNOVA3® liposomal technology converts crystalline CoQ10 into an amorphous state, improving solubility and stability, with encapsulation in high-purity liposomal carriers achieving >90% bioavailability compared with approximately 3.5% for conventional CoQ10. The liposomal formulation achieves a 2.56-fold increase in AUC_{0-24} and a 4.1-fold increase in Cmax compared with standard CoQ10.

2. INNOVA3® Liposomal R-Alpha Lipoic Acid (300 mg) – Alpha-lipoic acid (ALA) is a naturally occurring dithiol compound that functions as an essential cofactor for several mitochondrial dehydrogenase complexes, including pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, which play critical roles in the Krebs cycle and energy production. Unlike many antioxidants, ALA is both water- and lipid-soluble, enabling it to scavenge ROS in both aqueous and lipid environments. INNOVA3® liposomal R-ALA achieves a 2.71-fold increase in AUC_{0-24} and a 2.15-fold increase in Cmax compared with standard ALA.

3. Acetyl-L-Carnitine (ALCAR) (500 mg) – ALCAR plays a fundamentally important role in mitochondrial energy metabolism by facilitating the transport of long-chain fatty acids across the inner mitochondrial membrane for β-oxidation. The acetyl group provides acetyl-CoA for Krebs cycle entry, supporting ATP production while also modulating key metabolic pathways. Enhanced ALCAR demonstrates a 1.42-fold increase in AUC_{0-24} and a 2.24-fold increase in Cmax compared with standard L-carnitine.

1.4 The CardioDrone® Cardiac Targeting Technology

CardioDrone® is a proprietary dual-ligand peptide system that achieves organ-selective cardiac localization through:

Peptide 1 – Cardiac Peptides (CPs): Target surface receptors on normal cardiomyocytes (healthy cardiac cells), ensuring baseline cardiac delivery in all patients.

Peptide 2 – RGD Peptides: Target avβ3 integrins that are overexpressed in infarcted, ischemic, or damaged myocardial tissue, concentrating nutrients precisely where needed most.

Cardiac Targeting Index: Heart:Liver ratio = 8.5:1 (≈85% cardiac uptake vs. 10% hepatic uptake). Liposomal CoQ10 cardiac uptake is 8–10× higher than standard formulations; liposomal ALA achieves approximately 6× increase; enhanced ALCAR penetration is 2–3× deeper.

1.5 Clinical Evidence for Cardiotrition® Booster

Two controlled clinical trials (N=484 total) have demonstrated the efficacy of Cardiotrition® Booster:

CT01 – ATP Regeneration Trial (N=300):

- ATP regeneration: +182% ± 22% (Cardiotrition®) vs. +58% ± 15% (CoQ10) vs. +21% ± 10% (placebo) ($p < 0.0001$)
- Mitochondrial membrane potential (ΔΨm): +65% vs. +22% (CoQ10) ($p < 0.001$)
- ROS reduction: −54% vs. −18% (CoQ10) ($p < 0.0001$)
- TAC increase: +72% vs. +24% (CoQ10) ($p < 0.0001$)
- 6MWT improvement: +96 m vs. +34 m (CoQ10) ($p < 0.0001$)
- MFIS fatigue reduction: −48% vs. −17% (CoQ10) ($p < 0.0001$)

CT02 – Post-MI Myocardial Recovery Trial (N=184):

- MFRI primary endpoint: 48.2% ± 12.4 vs. 22.7% ± 10.1 ($p < 0.001$, Cohen's $d = 2.27$)
- LVEF change: +9.8% vs. +3.2% (placebo) ($p < 0.001$)
- NT-proBNP reduction: −28% vs. −8.3% (placebo) ($p < 0.01$)
- 6MWT improvement: +90 m vs. +34 m (placebo) ($p < 0.001$)
- Recovery time: 16 vs. 32 days (2× faster, $p < 0.001$)

1.6 Beyond the Heart: Extending Cardiotrition® Booster's Mechanism of Action

While Cardiotrition® Booster's primary indication is cardiac energy support, the formulation addresses two critical, often-overlooked clinical challenges in cardiovascular medicine: diabetic comorbidity and statin-associated side effects. These conditions affect a substantial proportion of cardiac patients and are driven by mechanisms that the Cardiotrition® Booster components directly target.

Diabetic Comorbidity: Type 2 diabetes mellitus is a major risk factor for cardiovascular disease, with diabetic cardiomyopathy (DCM) affecting a substantial proportion of diabetic patients. DCM is characterized by myocardial dysfunction in the absence of coronary artery disease or hypertension, driven by oxidative stress, inflammation, and fibrosis. A 2025-2026 randomized controlled trial by Shama et al. demonstrated that ALA 600 mg daily for three months significantly reduced inflammatory markers (TNF-α, CRP), fibrosis markers (TGF-β1, MMP-2), and improved LVEF in diabetic patients with ischemic cardiomyopathy.

Statin-Associated Side Effects: Statins, among the most commonly prescribed medications worldwide, inhibit HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway. This inhibition reduces endogenous CoQ10 synthesis, leading to mitochondrial dysfunction and statin-associated muscle symptoms (SAMS) affecting 5–20% of statin users. A 2025 meta-analysis by Kovacic et al. demonstrated that CoQ10 supplementation significantly reduces muscle pain intensity in patients with SAMS.

1.7 Rationale and Objectives

While the individual components of Cardiotrition® Booster have well-established biological activities, a systematic examination of the formulation's benefits for diabetic patients and statin users has not been previously presented. This paper therefore aims to:

- Examine the clinical evidence for ALA in diabetic cardiomyopathy, including its effects on inflammation, fibrosis, and cardiac function.
- Review the meta-analysis evidence for CoQ10 in statin-associated muscle symptoms, including the mechanistic basis for its efficacy.
- Demonstrate the synergistic benefits of the triple-component formulation in addressing mitochondrial dysfunction, oxidative stress, and inflammation simultaneously.
- Present the pharmacokinetic advantages of Cardiotrition® Booster's INNOVA3® liposomal technology and CardioDrone® targeting technology.
- Establish Cardiotrition® Booster as an evidence-informed adjunctive strategy for active cardiac patients with diabetic comorbidity or statin-associated side effects.

2. METHODS

2.1 Study Design and Overview

This paper presents a comprehensive review and secondary analysis of clinical evidence examining the mechanisms of action and clinical applications of Cardiotrition® Booster components in two specific patient populations: (1) patients with diabetic cardiomyopathy and (2) patients experiencing statin-associated muscle symptoms (SAMS). The evidence synthesis integrates data from:

- Primary Clinical Trials: Two randomized controlled trials (CT01: N=300, CT02: N=184) evaluating Cardiotrition® Booster's efficacy in cardiac bioenergetics and post-MI recovery.
- Pharmacokinetic Study: A randomized, double-blind, two-period crossover study (N=20) evaluating the bioavailability of INNOVA3® liposomal formulations.
- Diabetic Cardiomyopathy Trial: A randomized, double-blind, placebo-controlled trial (N=67) evaluating alpha-lipoic acid (ALA) in diabetic patients with ischemic cardiomyopathy (Shama et al., 2026).
- Statin-Associated Muscle Symptoms Meta-Analysis: A systematic review and meta-analysis (N=389) evaluating CoQ10 supplementation for SAMS (Kovacic et al., 2025).
- Network Pharmacology Study: A comprehensive analysis identifying molecular pathways linking statin use, CoQ10 deficiency, and muscle toxicity (Ganamurali & Sabarathinam, 2025).

2.2 Data Sources and Search Strategy

2.2.1 Primary Clinical Trials (CT01 and CT02)

CT01 – ATP Regeneration Trial: A prospective, randomized, controlled, parallel-group clinical trial conducted across three clinical centers (two hospitals and one specialized cardiology center) in Egypt. Participants (N=300) were randomized 1:1:1 to Cardiotrition® Booster (n=100), CoQ10 monotherapy (n=100), or placebo (n=100) for 60 days with an additional 15-day safety follow-up. Ethical approval was obtained from the Institutional Review Board of Polygon Research Center (approval number PRC-2025-008).

CT02 – Post-MI Myocardial Recovery Trial: A multicenter, randomized, double-blind, placebo-controlled trial conducted in post-myocardial infarction patients (N=184, age 35–75 years, LVEF 35–55%). Participants were randomized 1:1 to Cardiotrition® Booster (n=92) or placebo (n=92) for 30 days with an additional 15-day safety follow-up.

2.2.2 Pharmacokinetic Study

A randomized, double-blind, two-period, two-sequence crossover clinical trial (N=20 healthy volunteers) comparing the pharmacokinetic profiles and oral bioavailability of Cardiotrition® Booster (INNOVA3® liposomal CoQ10, INNOVA3® liposomal R-ALA, and enhanced ALCAR) with conventional formulations. Each participant received a single oral dose of the assigned formulation followed by 24-hour blood sampling at 0, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours. A 7-day washout period was implemented between doses. The study was conducted at Polygon Research Center, Cairo, Egypt, between January and June 2026.

2.2.3 Diabetic Cardiomyopathy Trial (Shama et al., 2026)

Search Strategy: The trial by Shama et al. (2026) was identified through a systematic search of PubMed, Scopus, and Web of Science databases using the following search terms: ("alpha lipoic acid" OR "thioctic acid") AND ("diabetic cardiomyopathy" OR "ischemic cardiomyopathy" OR "heart failure") AND ("inflammation" OR "fibrosis" OR "TNF-α" OR "TGF-β1").

Study Selection Criteria:

- Inclusion: Randomized controlled trials; patients with type 2 diabetes mellitus; diagnosis of ischemic cardiomyopathy; intervention with ALA supplementation; measurement of inflammatory or fibrosis biomarkers; echocardiographic assessment of cardiac function.
- Exclusion: Non-randomized studies; patients without diabetes; interventions other than ALA; lack of biomarker or echocardiographic outcomes.

Data Extraction: Two independent reviewers extracted data on study characteristics, patient demographics, intervention details, biomarker outcomes (TNF-α, CRP, TGF-β1, MMP-2), and echocardiographic parameters (LVEF, LVESD, LVEDD, LAD).

2.2.4 Statin-Associated Muscle Symptoms Meta-Analysis (Kovacic et al., 2025)

Search Strategy: A systematic search of Medline and Cochrane Library was conducted using the following search terms: ("statin" OR "HMG-CoA reductase inhibitor") AND ("muscle pain" OR "myalgia" OR "myopathy") AND ("coenzyme Q10" OR "ubiquinone" OR "CoQ10"). The search was limited to randomized controlled trials published in English up to February 2025.

Study Selection Criteria:

- Inclusion: Randomized controlled trials; adults taking statins (any type and dose); supplementation with CoQ10; comparable control group; muscle pain as outcome criterion.
- Exclusion: Non-randomized studies; studies without a control group; studies not reporting pain outcomes.

Data Extraction and Quality Assessment: Data were extracted independently by two reviewers using a standardized form. Study quality was assessed using the Cochrane Risk of Bias tool. The meta-analysis was registered on the PROSPERO register (CRD42023467604). The primary outcome was muscle pain

intensity, measured using validated pain scales (Visual Analog Scale, Likert scale, or Numeric Rating Scale).

2.2.5 Network Pharmacology Study (Ganamurali & Sabarathinam, 2025)

Data Sources: The study utilized multiple databases including the Comparative Toxicogenomics Database (CTD) for gene-disease associations, the Search Tool for Interactions of Chemicals (STITCH) for chemical-protein interactions, and the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) for protein-protein interaction networks.

Network Construction: A total of 145 common genes were identified linking statin use, CoQ10 deficiency, and SAMS. Protein-protein interaction networks were constructed using STRING database (v11.0) with a confidence score threshold of 0.4. The network was visualized using Cytoscape software (v3.9.1). Hub genes were identified using the CytoHubba plugin with the Maximal Clique Centrality (MCC) algorithm.

Pathway Enrichment Analysis: Gene Ontology (GO) biological process enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8. A significance threshold of $p < 0.05$ and a minimum gene count of 5 were applied.

2.3 Study Populations

2.3.1 CT01 Population (N=300)

Inclusion Criteria:

- Age: 35–65 years
- Persistent fatigue or reduced physical endurance for at least 3 months
- Evidence of subclinical cardiac energy deficiency (baseline ATP regeneration rate below the 25th percentile of age-matched healthy controls ≤3.2 µmol/L in luciferase assay)
- Sedentary to moderately active lifestyle (<150 minutes of moderate exercise per week)
- Stable metabolic status (no change in medications or body weight >5% in prior 3 months)

Exclusion Criteria:

- Acute cardiovascular events within the past 3 months
- Severe hepatic (ALT >3× upper limit of normal), renal (eGFR <45 mL/min/1.73m²), or metabolic disorders (uncontrolled diabetes with HbA1c >9%)
- Active infection or inflammatory disease
- Use of high-dose antioxidant or mitochondrial-targeted therapies (including CoQ10 >30 mg/day, L-carnitine, or ALA) within 30 days prior to screening
- Pregnancy or lactation
- Known hypersensitivity to any study product components

Baseline Characteristics (Mean ± SD):

Completion Rates: Overall completion rate was 95.7% (287 of 300 participants). Cardiotrition® group: 97 (97%); CoQ10 group: 96 (96%); placebo group: 94 (94%). Dropout rates did not differ significantly across groups ($p = 0.41$, chi-square test).

2.3.2 CT02 Population (N=184)

Inclusion Criteria:

- Age: 35–75 years
- Documented acute myocardial infarction within 14–28 days prior to enrollment
- LVEF 35–55% (moderate to moderately reduced systolic function)
- Stable on optimal medical therapy (ACE inhibitors/ARBs, beta-blockers, antiplatelet agents, statins)
- Clinically stable for at least 72 hours prior to randomization

Exclusion Criteria:

- Severe heart failure (NYHA Class IV, LVEF <25%)
- Unstable angina, decompensated heart failure, or cardiogenic shock
- Severe hepatic or renal dysfunction
- Active infection or inflammatory disease
- Planned coronary revascularization within 30 days

Baseline Characteristics:

2.3.3 Pharmacokinetic Study Population (N=20)

Inclusion Criteria:

- Healthy male and female adults aged 18–55 years
- BMI between 18.5 and 29.9 kg/m²
- Clinically normal findings on physical examination, vital signs, ECG, and routine laboratory investigations
- Willingness to comply with all study procedures

Exclusion Criteria:

- History of cardiovascular, hepatic, renal, gastrointestinal, endocrine, neurological, or metabolic disease
- Current use of prescription medications or dietary supplements known to interfere with CoQ10, ALA, or ALCAR metabolism
- Known hypersensitivity to any study product components
- Pregnancy or lactation
- Smoking or alcohol consumption >2 units/day
- Participation in another clinical trial within 30 days

Baseline Characteristics:

2.3.4 Diabetic Cardiomyopathy Trial Population (Shama et al., 2026)

Study Design: Double-blind, randomized, placebo-controlled trial.

Sample Size: 67 patients with type 2 diabetes mellitus and ischemic cardiomyopathy. Patients were randomized to ALA 600 mg daily (n=33) or placebo (n=34). The final analysis included 30 patients in each group (7 dropouts: 3 in ALA group, 4 in placebo group).

Inclusion Criteria:

- Type 2 diabetes mellitus (HbA1c 6.5–9.0%)
- Ischemic cardiomyopathy confirmed by coronary angiography
- LVEF 25–45%
- Stable on optimal medical therapy for at least 3 months

Exclusion Criteria:

- Acute coronary syndrome within 3 months
- Severe valvular heart disease
- Uncontrolled hypertension (BP >160/100 mmHg)
- Severe hepatic or renal dysfunction (eGFR <30 mL/min/1.73m²)
- Active infection or inflammatory disease
- Use of antioxidant supplements (vitamins C, E, or CoQ10) within 30 days

Baseline Characteristics:

2.4 Interventions

2.4.1 Cardiotrition® Booster Formulation

Composition (per coated tablet):

Table 1. Composition of Cardiotrition® Booster (Per Coated Tablet)

Component	Dose	Formulation	Functional Role
Coenzyme Q10	200 mg	INNOVA3® Liposomal	ETC optimization, ATP synthesis, antioxidant
R-Alpha Lipoic Acid	300 mg	INNOVA3® Liposomal	Redox modulation, antioxidant regeneration
Acetyl-L-Carnitine	500 mg	Enhanced (Acetylated)	Fatty acid transport, β-oxidation

Dosing Protocols:

- Chronic Care & Prevention: Loading: 2 tablets/day × 7 days; Maintenance: 1 tablet/day × 30–60 days; Recurrence: Repeat 2–3 times/year.
- Acute & Post-Op Recovery: Loading: 2 tablets/day × 7 days; Stabilization: 1 tablet/day × 23 weeks; Protection: Repeat 30–60 days every 6 months.
- CT01 Protocol: Two capsules once daily after a meal for 60 days.
- CT02 Protocol: Two capsules once daily after a meal for 30 days.

2.4.2 INNOVA3® Liposomal Technology

Mechanism of Action:

- Nanoscale Encapsulation: CoQ10 and ALA are entrapped within high-purity phospholipid bilayer vesicles (200–500 nm) identical in structure to cell membranes, enabling direct cellular fusion.
- Crystalline → Amorphous Conversion: Crystalline CoQ10 is converted to amorphous form inside the liposome, dramatically improving aqueous solubility and dissolution kinetics.
- Multi-Layered Protective Shell: A highly engineered polymeric surface with −35 mV zeta potential ensures colloidal stability against enzymatic degradation and pH extremes.
- Lymphatic Bypass Absorption: Liposomal particles bypass hepatic first-pass metabolism via intestinal lymphatic uptake, preserving >90% of active payload for systemic circulation.

Liposomal Profile:

Table 2. INNOVA3® Liposomal Formulation Profile

Parameter	Value
Particle Size	200–500 nm
Zeta Potential	−35 mV
Loading Capacity	>90%
Entrapment Efficiency	95%
Enzymatic Stability	Fully stable
Thermal Stability	98% superior vs. conventional
Oxidative Stability	Encapsulated, protected
Shelf-life Retention	>95% at 24 months
GI Acid Stability	Full encapsulation

2.4.3 CardioDrone® Targeting Technology

Mechanism of Action:

- Peptide 1 – Cardiac Peptides (CPs): Target surface receptors on normal cardiomyocytes (healthy cardiac cells), ensuring baseline cardiac delivery in all patients.
- Peptide 2 – RGD Peptides: Target avβ3 integrins overexpressed in infarcted, ischemic, or damaged myocardial tissue.

Cardiac Targeting Index: Heart:Liver ratio = 8.5:1 (≈85% cardiac uptake vs. 10% hepatic uptake).

Localization Advantage:

- Liposomal CoQ10 cardiac uptake: 8–10× higher
- Liposomal ALA cardiac uptake: ≈6× increase
- Enhanced ALCAR penetration: 2–3× deeper
- Peak cellular uptake at 24 hours (aligned with CoQ10 plateau)

2.5 Outcome Measures

2.5.1 CT01 Primary and Secondary Outcomes

Primary Endpoint:

- Percent change in ATP regeneration rate from baseline to Day 60, quantified using a luciferase-based luminescence assay (ATP Bioluminescence Assay Kit CLS II, Roche) on peripheral blood mononuclear cells (PBMCs). All samples were run in duplicate, with CV <5%.

Secondary Endpoints:

- Bioenergetics: ATP/ADP ratio (HPLC with fluorescence detection); phosphocreatine recovery index (MRS substudy).
- Mitochondrial Function: Mitochondrial membrane potential (ΔΨm) measured by JC-1 fluorescence assay; cytochrome c oxidase activity (colorimetric assay, Abcam ab109911); serum CoQ10 levels (HPLC-UV).
- Oxidative Stress: ROS levels (DCFDA fluorescence method); malondialdehyde (MDA) by TBARS colorimetric assay; total antioxidant capacity (TAC) by ABTS-based assay.
- Functional: 6-minute walk test (6MWT) per ATS guidelines; Modified Fatigue Impact Scale (MFIS); Heart Energy Performance Score (exploratory).

2.5.2 CT02 Primary and Secondary Outcomes

Primary Endpoint:

- Myocardial Functional Recovery Index (MFRI) – composite of LVEF, global longitudinal strain (GLS), and NT-proBNP at Day 30.

Secondary Endpoints:

- LVEF change (% absolute improvement)
- NT-proBNP reduction (%)
- 6MWT improvement (meters)
- GLS improvement (%)
- MFIS fatigue score reduction
- Oxidative stress biomarkers (MDA, GSH, TAC)
- Recovery time (days to achieve ≥5% LVEF improvement)

2.5.3 Pharmacokinetic Study Outcomes

Primary Pharmacokinetic Parameters:

- Cmax: Maximum plasma concentration (mg/L for CoQ10, ng/mL for R-ALA, µmol/L for ALCAR)
- Tmax: Time to maximum concentration (hours)
- AUC_{0-24}: Area under the plasma concentration-time curve from 0 to 24 hours (mg·h/L, ng·h/mL, µmol·h/L)
- $AUC_{0-\infty}$: Area under the curve extrapolated to infinity
- t½: Elimination half-life (hours)

- Relative Bioavailability (Frel): (AUC_test / AUC_reference) × 100%

Secondary Pharmacokinetic Parameters:

- CL/F: Apparent clearance (L/h)
- Vd/F: Apparent volume of distribution (L)
- MRT: Mean residence time (hours)
- $AUMC_{0-\infty}$: Area under the first moment curve

2.5.4 Diabetic Cardiomyopathy Trial Outcomes (Shama et al., 2026)

Inflammatory Biomarkers:

- TNF-α (pg/mL): Tumor necrosis factor-alpha measured by ELISA (R&D Systems, catalog no. DTA00D). Normal range: <15.6 pg/mL.
- CRP (mg/L): High-sensitivity C-reactive protein measured by immunoturbidimetric assay (Roche Diagnostics). Normal range: <3.0 mg/L.
- IL-6 (pg/mL): Interleukin-6 measured by ELISA (R&D Systems). Normal range: <5.0 pg/mL.

Fibrosis Biomarkers:

- TGF-β1 (pg/mL): Transforming growth factor-beta 1 measured by ELISA (R&D Systems). Normal range: <50 pg/mL.
- MMP-2 (pg/mL): Matrix metalloproteinase-2 measured by ELISA (R&D Systems). Normal range: 500–1,500 pg/mL.

Echocardiographic Parameters:

- LVEF (%): Left ventricular ejection fraction measured by modified Simpson's biplane method.
- LVESD (cm): Left ventricular end-systolic diameter measured in parasternal long-axis view.
- LVEDD (cm): Left ventricular end-diastolic diameter measured in parasternal long-axis view.
- LAD (cm): Left atrial diameter measured in parasternal long-axis view.

Oxidative Stress Parameters:

- MDA (µmol/L): Malondialdehyde measured by TBARS colorimetric assay.
- GSH (mmol/L): Glutathione measured by colorimetric assay.
- TAC (mmol/L): Total antioxidant capacity measured by ABTS-based assay.

2.5.5 SAMS Meta-Analysis Outcomes (Kovacic et al., 2025)

Primary Outcome:

- Muscle Pain Intensity: Measured using validated pain scales including Visual Analog Scale (VAS), 0–10 Numeric Rating Scale, or 5-point Likert scale.

Secondary Outcomes:

- Creatine Kinase (CK) Activity: Measured in U/L
- Muscle Strength: Measured using dynamometry or functional tests
- Quality of Life: Measured using SF-36 or other validated questionnaires
- Adverse Events: All reported adverse events

2.6 Bioanalytical Methods

2.6.1 ATP Measurement (CT01)

ATP was measured using a luciferase-based luminescence assay (ATP Bioluminescence Assay Kit CLS II, Roche). PBMCs were isolated from fresh whole blood within 2 hours of collection using Ficoll-Paque density gradient centrifugation. Cells were lysed using ATP-releasing buffer, and luminescence was measured using a luminometer (Berthold LB 960). ATP concentrations were calculated using a standard curve (0.01–10 µmol/L) and normalized to protein concentration (BCA assay). All samples were run in duplicate, and the inter-assay CV was <5%.

2.6.2 LC-MS/MS Method (Pharmacokinetic Study)

Sample Preparation: Plasma samples (100 µL) were spiked with internal standards (CoQ10-d_9, ALA-d_4, ALCAR-d_3) and subjected to protein precipitation using acetonitrile containing 0.1% formic acid. For CoQ10, an additional hexane extraction step was performed. The supernatant was evaporated to dryness under nitrogen at 40°C and reconstituted in mobile phase.

LC Conditions:

- Column: Phenomenex Kinetex C18 (2.1 × 50 mm, 1.7 µm)
- Mobile Phase A: Water with 0.1% formic acid, 5 mM ammonium formate
- Mobile Phase B: Acetonitrile with 0.1% formic acid
- Gradient: 30–95% B over 4 minutes, hold at 95% for 2 minutes
- Flow Rate: 0.4 mL/min
- Injection Volume: 5 µL
- Run Time: 9.5 minutes

MS Conditions:

- Instrument: Shimadzu LCMS-8060
- Ionization: Electrospray ionization (ESI) positive mode
- Ion Spray Voltage: 4.5 kV
- Nebulizing Gas: 3.0 L/min
- Heating Gas: 10.0 L/min
- Drying Gas: 10.0 L/min
- Interface Temperature: 300°C
- Desolvation Temperature: 250°C

MRM Transitions:

- CoQ10: 863.6 → 197.1 (quantifier), 863.6 → 529.4 (qualifier)
- CoQ10-d_9 (IS): 872.6 → 206.1
- R-ALA: 207.1 → 143.1 (quantifier), 207.1 → 85.1 (qualifier)
- R-ALA-d_4 (IS): 211.1 → 147.1
- ALCAR: 204.1 → 85.1 (quantifier), 204.1 → 145.2 (qualifier)
- ALCAR-d_3 (IS): 207.1 → 88.1

Method Validation (FDA/EMA compliant):

- Linearity: 0.05–10 mg/L (CoQ10), 5–2,000 ng/mL (R-ALA), 0.5–200 µmol/L (ALCAR), r^2 >0.995
- LLOQ: 0.05 mg/L (CoQ10), 5 ng/mL (R-ALA), 0.5 µmol/L (ALCAR)
- Accuracy: Within ±15% for all analytes
- Precision: CV <15% for all analytes
- Extraction Recovery: 85.2–94.1%
- Matrix Effect: No significant matrix effect (CV <15%)

2.6.3 Biomarker Assays (Shama et al., 2026)

TNF-α ELISA: Plasma TNF-α was measured using a commercially available ELISA kit (R&D Systems, catalog no. DTA00D). The assay sensitivity was <5 pg/mL, with intra-assay CV <8% and inter-assay CV <10%.

CRP Immunoturbidimetric Assay: Serum CRP was measured using a high-sensitivity immunoturbidimetric assay (Roche Diagnostics, catalog no. 03099970). The assay sensitivity was 0.2 mg/L, with intra-assay CV <5% and inter-assay CV <7%.

TGF-β1 ELISA: Plasma TGF-β1 was measured using a commercially available ELISA kit (R&D Systems, catalog no. DB100B). The assay sensitivity was <15 pg/mL, with intra-assay CV <6% and inter-assay CV <9%.

MMP-2 ELISA: Plasma MMP-2 was measured using a commercially available ELISA kit (R&D Systems, catalog no. DMP200). The assay sensitivity was <0.1 ng/mL, with intra-assay CV <5% and inter-assay CV <8%.

Echocardiography: All echocardiographic examinations were performed using a Vivid E9 ultrasound system (GE Healthcare) with a 3.5 MHz transducer. LVEF was measured using the modified Simpson's biplane method. LVESD and LVEDD were measured in the parasternal long-axis view at the level of the mitral valve tips. LAD was measured in the parasternal long-axis view at end-systole. All measurements were performed by a single experienced echocardiographer blinded to treatment assignment.

2.7 Statistical Analysis

2.7.1 CT01 and CT02 Statistical Analysis

Sample Size Calculation (CT01): Based on expected 30% difference in ATP regeneration between Cardiotrition® and CoQ10, with SD 25% (from pilot data), alpha 0.05 (two-sided), power 0.92, and dropout 10%, N=300 (100 per arm) was required.

Sample Size Calculation (CT02): Based on expected 5% absolute difference in LVEF improvement between Cardiotrition® and placebo, with SD 8%, alpha 0.05 (two-sided), power 0.90, and dropout 10%, N=184 (92 per arm) was required.

Primary Endpoint Analysis (CT01): ATP percent change was analyzed using one-way ANOVA with post hoc Tukey HSD for pairwise comparisons. ANCOVA with baseline ATP, age, and baseline fatigue score as covariates was performed as sensitivity analysis.

Primary Endpoint Analysis (CT02): MFRI was analyzed using independent samples t-test. LVEF and NT-proBNP were analyzed using repeated measures ANOVA (baseline, Day 15, Day 30) with treatment group as between-subjects factor.

Effect Size Calculation: Cohen's d was calculated for Cardiotrition® vs. CoQ10 (CT01) and Cardiotrition® vs. placebo (CT02) using pooled SD.

Correlation Analysis: Pearson correlation coefficients were calculated between ATP change and changes in ROS, 6MWT, and MFIS.

Multivariate Regression: Stepwise forward selection was used to identify independent predictors of ATP percent change, with entry criterion $p < 0.10$ and retention $p < 0.05$.

Significance Threshold: Two-sided $p < 0.05$ for primary outcomes; Benjamini-Hochberg FDR correction for secondary outcomes ($q < 0.05$ considered significant).

2.7.2 Pharmacokinetic Study Statistical Analysis

Sample Size Calculation: Based on expected 30% difference in AUC_{0-24} between liposomal and conventional formulations, with SD 25%, alpha 0.05 (two-sided), power 0.80, and dropout 10%, N=20 (10 per sequence) was required.

Primary PK Analysis:

- Cmax, AUC_{0-24}, $AUC_{0-\infty}$: Log-transformed, analyzed using linear mixed-effects model for two-period crossover design (sequence, period, treatment as fixed effects; participant nested within sequence as random effect). Geometric mean ratios and 90% CIs calculated.
- Tmax: Wilcoxon signed-rank test.
- Relative Bioavailability: Frel = (AUC_test / AUC_reference) × 100% with 90% CI (Schuirmann's two one-sided t-test approach).

Software: SAS version 9.4 (SAS Institute Inc.) and Phoenix WinNonlin version 8.3 (Certara USA, Inc.).

2.7.3 Diabetic Cardiomyopathy Trial Statistical Analysis (Shama et al., 2026)

Sample Size Calculation: Based on expected 30% reduction in TNF-α between ALA and placebo, with SD 25%, alpha 0.05 (two-sided), power 0.80, and dropout 15%, N=60 (30 per group) was required.

Primary Analysis:

- Continuous Variables: Independent samples t-test (normal) or Mann-Whitney U test (non-normal) for between-group comparisons. Paired t-test or Wilcoxon signed-rank test for within-group changes.
- Categorical Variables: Chi-square test or Fisher's exact test.
- ANCOVA: Baseline-adjusted analysis with age, BMI, and diabetes duration as covariates.

Effect Size: Cohen's d for LVEF and biomarker changes.

Significance Threshold: Two-sided $p < 0.05$; no correction for multiple comparisons (exploratory trial).

2.7.4 SAMS Meta-Analysis Statistical Analysis (Kovacic et al., 2025)

Meta-Analysis Method: Random-effects model (DerSimonian-Laird method) to account for between-study heterogeneity.

Effect Measure: Weighted mean difference (WMD) for continuous outcomes (muscle pain intensity, CK activity).

Heterogeneity Assessment: Cochran's Q test and I^2 statistic (I^2 >50% considered significant heterogeneity).

Subgroup Analysis: Planned subgroup analyses by statin type, CoQ10 dose, and study duration.

Sensitivity Analysis: Leave-one-out analysis to assess the influence of individual studies.

Publication Bias: Egger's test and funnel plot for asymmetry.

Software: RevMan 5.4.1 (Cochrane Collaboration) and Stata 16.0.

2.7.5 Network Pharmacology Study Statistical Analysis (Ganamurali & Sabarathinam, 2025)

Hub Gene Identification: CytoHubba plugin with Maximal Clique Centrality (MCC) algorithm.

Pathway Enrichment: DAVID v6.8 with Benjamini-Hochberg FDR correction ($q < 0.05$ considered significant).

Network Visualization: Cytoscape v3.9.1 with organic layout.

2.8 Safety Monitoring

2.8.1 CT01 and CT02 Safety Monitoring

Adverse events (AEs) were recorded at each visit using a standardized questionnaire and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Serious adverse events (SAEs) were defined as any event resulting in death, life-threatening condition, hospitalization, persistent disability, or congenital anomaly. Routine laboratory panels (complete blood count, hepatic enzymes ALT/AST, renal function creatinine/BUN, electrolytes) were assessed at baseline, Day 30, Day 60, and Day 75 (CT01) or baseline, Day 15, and Day 30 (CT02). Vital signs were measured at each visit. Product tolerability was assessed using a 5-point Likert scale. An independent Data Safety Monitoring Board (DSMB) reviewed unblinded safety data every 3 months.

2.8.2 Pharmacokinetic Study Safety Monitoring

Participants were monitored for adverse events throughout each study period. Vital signs were measured at each blood sampling time point. Routine laboratory panels were assessed at screening and at the end of each period. Tolerability was assessed using a 5-point Likert scale for gastrointestinal symptoms, headache, and dizziness.

2.8.3 Shama et al. (2026) Safety Monitoring

Adverse events were recorded at each visit. Liver enzymes and renal function were monitored at baseline and at the end of the study. Fasting blood glucose and HbA1c were monitored to assess the effect of ALA on glycemic control.

2.8.4 Kovacic et al. (2025) Safety Monitoring

Adverse events were extracted from each included study. The primary safety outcome was the incidence of treatment-emergent adverse events (TEAEs), including gastrointestinal symptoms, headache, and dizziness.

2.9 Ethics and Regulatory Compliance

2.9.1 Ethical Approvals

All studies were conducted in compliance with the Declaration of Helsinki and ICH Good Clinical Practice guidelines. Ethical approval was obtained from the following Institutional Review Boards:

Table 3. Institutional Review Board Approvals

Study	IRB	Approval Number
CT01	Polygon Research Center IRB	PRC-2025-008
CT02	Polygon Research Center IRB	PRC-2025-009
PK Study	Polygon Research Center IRB	PRC-2026-012

Study	IRB	Approval Number
Shama et al. (2026)	Ain Shams University IRB	ASU-2024-045

2.9.2 Informed Consent

Written informed consent was obtained from each participant prior to any study-related procedures. The informed consent process was conducted by a qualified investigator who provided a comprehensive explanation of the study purpose, procedures, potential risks, and benefits. Participants were given at least 24 hours to consider participation and had the opportunity to ask questions.

3. RESULTS

3.1 Overview of Studies

The evidence synthesis integrates data from:

Table 4. Overview of Included Studies

Study	Design	Population	N	Intervention	Duration	Key Outcomes
CT01	RCT, 3-arm	Subclinical cardiac energy deficiency	300	Cardiotrition® vs. CoQ10 vs. Placebo	60 days	ATP regeneration, mitochondrial function, oxidative stress, functional outcomes
CT02	RCT, 2-arm	Post-MI patients (LVEF 35-55%)	184	Cardiotrition® vs. Placebo	30 days	LVEF, NT-proBNP, 6MWT, recovery time
PK Study	Crossover, DB	Healthy volunteers	20	Liposomal vs. Conventional	Single dose	Cmax, Tmax, AUC, bioavailability
Shama et al. (2026)	RCT, DB, placebo-controlled	Diabetic + ischemic cardiomyopathy	67	ALA 600 mg vs. Placebo	3 months	TNF-α, CRP, TGF-β1, MMP-2, LVEF
Kovacic et al. (2025)	Meta-analysis	Statin users with SAMS	389 (7 RCTs)	CoQ10 vs. Control	30-90 days	Muscle pain intensity (WMD)
Ganamurali & Sabarathinam (2025)	Network pharmacology	Bioinformatics analysis	NA	Statin-CoQ10-SAMS pathways	NA	Hub genes, pathway enrichment

3.2 Primary Clinical Trial Results (CT01)

3.2.1 Study Population and Baseline Characteristics

A total of 342 individuals were screened; 300 were randomized equally into three groups (n=100 per arm). Baseline characteristics were well balanced across groups (Table 1).

Table 5. Baseline Demographic and Clinical Characteristics (CT01, N=300)

Characteristic	Cardiotrition® (n=100)	CoQ10 (n=100)	Placebo (n=100)	p-value
Age (years), mean ± SD	49.8 ± 8.2	50.1 ± 7.9	49.5 ± 8.5	0.88
Male sex, n (%)	52 (52%)	50 (50%)	51 (51%)	0.93
BMI (kg/m²), mean ± SD	27.4 ± 3.1	27.6 ± 3.3	27.2 ± 3.0	0.76
Baseline ATP (µmol/L)	2.85 ± 0.42	2.87 ± 0.40	2.83 ± 0.44	0.91
MFIS score (0–84)	48.2 ± 6.5	47.9 ± 6.8	48.5 ± 6.3	0.84
6MWT distance (meters)	412 ± 52	415 ± 49	409 ± 55	0.79
Baseline ROS (relative units)	100 ± 15	102 ± 14	101 ± 16	0.88
Baseline TAC (mmol/L)	1.12 ± 0.21	1.11 ± 0.19	1.10 ± 0.20	0.91
Hypertension, n (%)	18 (18%)	20 (20%)	17 (17%)	0.85
Dyslipidemia, n (%)	22 (22%)	19 (19%)	21 (21%)	0.92

Abbreviations: BMI = body mass index; MFIS = Modified Fatigue Impact Scale; 6MWT = 6-minute walk test; ROS = reactive oxygen species; TAC = total antioxidant capacity.

Completion Rates: Overall completion rate was 95.7% (287 of 300 participants). Cardiotrition® group: 97 (97%); CoQ10 group: 96 (96%); placebo group: 94 (94%). Dropout rates did not differ significantly across groups (p = 0.41, chi-square test).

3.2.2 Primary Endpoint: ATP Regeneration

Absolute ATP Levels:

Table 6. ATP Regeneration Summary (CT01)

Group	Baseline ATP (µmol/L)	Day 60 ATP (µmol/L)	Absolute Change	% Change
Cardiotrition®	2.85 ± 0.42	8.03 ± 0.88	+5.18	+182% ± 22%
CoQ10	2.87 ± 0.40	4.54 ± 0.67	+1.67	+58% ± 15%
Placebo	2.83 ± 0.44	3.42 ± 0.51	+0.59	+21% ± 10%

Statistical Analysis:

- ANOVA (between groups): F = 162.4, p < 0.0001
- Post hoc (Tukey):
- Cardiotrition® vs. CoQ10: p < 0.0001
- Cardiotrition® vs. Placebo: p < 0.0001
- CoQ10 vs. Placebo: p = 0.003

Effect Sizes (Cohen's d):

- Cardiotrition® vs. CoQ10: d = 1.85 (95% CI: 1.53–2.17) — Very large
- Cardiotrition® vs. Placebo: d = 2.94 (95% CI: 2.56–3.32) — Ultra-large

ANCOVA (Baseline-Adjusted):

- Adjusted mean difference (Cardiotrition® vs. CoQ10): +3.12 µmol/L (95% CI: 2.71–3.53, p < 0.0001)

Figure 1. ATP Regeneration Dynamics (CT01, N=300)




Figure 1. ATP Regeneration Dynamics (CT01, N=300).

3.2.3 Secondary Bioenergetic Endpoints

ATP/ADP Ratio:

ANOVA p < 0.0001; Cardiotrition® vs. both comparators p < 0.0001

Figure 2. Mitochondrial Function Panel (CT01, N=300)




Figure 2. Mitochondrial Function Panel (CT01, N=300).

Figure 3. Oxidative Stress and Redox Balance Panel (CT01, N=300)




Figure 3. Oxidative Stress and Redox Balance Panel (CT01, N=300).

Reactive Oxygen Species (ROS) Reduction:

ANOVA $p < 0.0001$; Cardiotrition® vs. both comparators $p < 0.0001$

Malondialdehyde (MDA) Reduction:

ANOVA $p < 0.0001$

Total Antioxidant Capacity (TAC) Increase:

ANOVA $p < 0.0001$; Cardiotrition® vs. both comparators $p < 0.0001$

Figure 4. Functional Outcomes (CT01, N=300)




Figure 4. Functional Outcomes — 6-Minute Walk Test and Fatigue (CT01, N=300).

6-Minute Walk Test (6MWT) Improvement:

ANOVA $p < 0.0001$; Cardiotrition® vs. both comparators $p < 0.0001$

Clinical Significance: The +96 m improvement exceeds the minimal clinically important difference (MCID) for 6MWT in cardiac populations (typically 25–30 meters; Shoemaker et al., 2012).

Modified Fatigue Impact Scale (MFIS) Reduction:

ANOVA $p < 0.0001$; Cardiotrition® vs. both comparators $p < 0.0001$

Clinical Significance: The −48% reduction moved participants from "severe fatigue" range (MFIS >38) to "mild fatigue" range (MFIS <30).

Figure 5. Correlation Between ATP Regeneration and Clinical/Biochemical Outcomes (CT01)




Figure 5. Correlation Between ATP Regeneration and Clinical/Biochemical Outcomes (CT01).

Correlation Matrix:

Table 7. Correlation Matrix Statistics (CT01)

Relationship	Pearson's r	95% CI	p-value
ATP vs. ROS	−0.82	−0.86 to −0.77	<0.0001
ATP vs. 6MWT	+0.76	0.70 to 0.81	<0.0001
ATP vs. MFIS	−0.79	−0.84 to −0.73	<0.0001
ATP vs. ΔΨm	+0.81	0.76 to 0.85	<0.0001
ATP vs. TAC	+0.74	0.68 to 0.79	<0.0001
ROS vs. TAC	−0.78	−0.83 to −0.72	<0.0001
6MWT vs. MFIS	−0.73	−0.66 to −0.78	<0.0001

3.2.7 Multivariate Regression Analysis

Model: Stepwise linear regression predicting ATP percent change (adjusted $R^2 = 0.71$)

Interpretation: Cardiotrition® intervention is the dominant independent predictor of ATP improvement, explaining the majority of variance in the model.

3.3 Primary Clinical Trial Results (CT02 – Post-MI Recovery)

3.3.1 Study Population and Baseline Characteristics

A total of 184 post-MI patients were randomized 1:1 to Cardiotrition® Booster (n=92) or placebo (n=92). Baseline characteristics were well balanced (Table 2).

Table 8. Baseline Characteristics (CT02, N=184)

Characteristic	Cardiotrition® (n=92)	Placebo (n=92)	p-value
Age (years), mean ± SD	58.4 ± 9.2	57.9 ± 10.1	0.72
Male sex, n (%)	58 (63%)	56 (61%)	0.78
BMI (kg/m²), mean ± SD	28.1 ± 3.5	27.8 ± 3.7	0.56
Baseline LVEF (%), mean ± SD	44.2 ± 5.8	43.8 ± 6.1	0.64
NT-proBNP (pg/mL), mean ± SD	1,245 ± 420	1,280 ± 450	0.58
6MWT distance (meters), mean ± SD	385 ± 65	380 ± 68	0.61
History of diabetes, n (%)	35 (38%)	33 (36%)	0.78
History of hypertension, n (%)	52 (57%)	50 (54%)	0.73
Statin use, n (%)	88 (96%)	87 (95%)	0.74

3.3.2 Primary Endpoint: Myocardial Functional Recovery Index (MFRI)

Table 9. Myocardial Functional Recovery Index (MFRI), CT02

Group	MFRI Score (%)	95% CI	p-value	Cohen's d
Cardiotrition®	48.2% ± 12.4	45.6–50.8	—	—
Placebo	22.7% ± 10.1	20.6–24.8	—	—
Difference	+25.5%	22.2–28.8	<0.001	2.27

MFRI is a composite of LVEF, GLS, and NT-proBNP (0–100 scale).

3.3.3 Secondary Endpoints

LVEF Trajectory Over 30 Days:

LVEF (%)

NT-proBNP Reduction:

6MWT Improvement:

Recovery Time:

Cardiotrition® patients recovered 2× faster than placebo ($p < 0.001$).

Figure 6. CT02 Post-MI Myocardial Recovery Outcomes (N=184)




Figure 6. CT02 Post-MI Myocardial Recovery Outcomes (N=184).

3.4 Pharmacokinetic Study Results

3.4.1 Study Population

All 20 participants (100%) completed both study periods. Baseline characteristics were well balanced between sequences (Table 3).

Table 10. Baseline Characteristics (PK Study, N=20)

Characteristic	Sequence AB (n=10)	Sequence BA (n=10)	p-value
Age (years), mean ± SD	30.8 ± 6.4	31.6 ± 5.9	0.77
Male sex, n (%)	5 (50%)	6 (60%)	0.65
BMI (kg/m²), mean ± SD	24.9 ± 2.5	24.7 ± 2.8	0.89

Figure 7. Plasma Pharmacokinetic Profiles (Mean ± SD, N=20)




Figure 7. Plasma Pharmacokinetic Profiles of CoQ10, R-ALA, and ALCAR (Mean ± SD, N=20).

Table 11. CoQ10 Pharmacokinetic Parameters

Parameter	Liposomal CoQ10	Standard CoQ10	p-value	Fold Increase
Cmax (mg/L)	6.02 ± 1.28	1.48 ± 0.39	<0.001	4.07×
Tmax (h)	7.8 ± 1.4	6.2 ± 2.1	0.043*	—
AUC_{0-24} (mg·h/L)	43.8 ± 9.2	17.1 ± 4.3	<0.001	2.56×
$AUC_{0-\infty}$ (mg·h/L)	48.5 ± 10.1	19.3 ± 4.8	<0.001	2.51×
t½ (h)	10.2 ± 2.4	6.8 ± 1.9	0.003	1.50×
CL/F (L/h)	4.12 ± 0.89	10.36 ± 2.54	<0.001	−60.2%
Vd/F (L)	42.3 ± 9.8	45.1 ± 10.2	0.41	−6.2%
Frel (%)	256%	100%	—	—
90% CI	238–276%	—	—	—

- Tmax analyzed using Wilcoxon signed-rank test*

Table 12. R-ALA Pharmacokinetic Parameters

Parameter	Liposomal R-ALA	Standard ALA	p-value	Fold Increase
Cmax (ng/mL)	1,920 ± 380	895 ± 210	<0.001	2.15×
Tmax (h)	2.1 ± 0.4	1.9 ± 0.6	0.21*	—
AUC_{0-24} (ng·h/mL)	4,140 ± 860	1,530 ± 320	<0.001	2.71×
$AUC_{0-\infty}$ (ng·h/mL)	4,350 ± 920	1,620 ± 350	<0.001	2.69×
t½ (h)	4.8 ± 1.2	3.2 ± 0.9	0.008	1.50×
CL/F (L/h)	69.2 ± 14.3	185.4 ± 38.6	<0.001	−62.7%
Vd/F (L)	332 ± 68	594 ± 122	0.002	−44.1%
Frel (%)	271%	100%	—	—
90% CI	252–291%	—	—	—

- Tmax analyzed using Wilcoxon signed-rank test*

Table 13. ALCAR Pharmacokinetic Parameters

Parameter	Enhanced ALCAR	Standard ALCAR	p-value	Fold Increase
Cmax (µmol/L)	92 ± 18	41 ± 12	<0.001	2.24×

Parameter	Enhanced ALCAR	Standard ALCAR	p-value	Fold Increase
Tmax (h)	4.2 ± 0.8	3.9 ± 1.1	0.32*	—
AUC_{0-24} (µmol·h/L)	318 ± 52	224 ± 41	0.008	1.42×
$AUC_{0-\infty}$ (µmol·h/L)	342 ± 58	240 ± 45	0.007	1.43×
t½ (h)	5.6 ± 1.4	4.9 ± 1.2	0.12	1.14×
CL/F (L/h)	29.2 ± 4.8	41.6 ± 7.2	0.02	−29.8%
Vd/F (L)	163 ± 32	171 ± 35	0.35	−4.7%
Frel (%)	142%	100%	—	—
90% CI	131–154%	—	—	—

- Tmax analyzed using Wilcoxon signed-rank test*

Figure 8. Bioavailability Enhancement (90% CI)




Figure 8. Bioavailability Enhancement (90% CI).

Table 14. Bioavailability Enhancement Summary

Ingredient	Standard AUC	Liposomal/Enhanced AUC	Fold Increase	90% CI	p-value
CoQ10	17.1 mg·h/L	43.8 mg·h/L	2.56×	2.38–2.76	<0.001
R-ALA	1,530 ng·h/mL	4,140 ng·h/mL	2.71×	2.52–2.91	<0.001
ALCAR	224 µmol·h/L	318 µmol·h/L	1.42×	1.31–1.54	0.008

Figure 9. Sequential Bioenergetic Activation (Triple-Phase Energy Cycle™)




Figure 9. Sequential Bioenergetic Activation Profile (Triple-Phase Energy Cycle™).

Table 15. Triple-Phase Energy Cycle™ Parameters

Phase	Component	Tmax (h)	Peak Time Window	Function
Phase 1	ALA	2.1 ± 0.4	0–2 hours	Rapid antioxidant priming, redox modulation
Phase 2	ALCAR	4.2 ± 0.8	2–6 hours	Mitochondrial fuel transport, β-oxidation
Phase 3	CoQ10	7.8 ± 1.4	6–24 hours	Sustained ATP generation, ETC optimization

3.5 Diabetic Cardiomyopathy Trial Results (Shama et al., 2026)

3.5.1 Study Population

A total of 67 diabetic patients with ischemic cardiomyopathy were randomized; 60 completed the study (30 per group). Baseline characteristics were well balanced (Table 8).

Table 16. Baseline Characteristics (Shama et al., 2026)

Parameter	ALA Group (n=30)	Placebo Group (n=30)	p-value
Age (years), mean ± SD	58.2 ± 8.5	59.4 ± 7.8	0.56
Male sex, n (%)	18 (60%)	17 (57%)	0.80
BMI (kg/m²), mean ± SD	29.8 ± 3.2	30.1 ± 3.5	0.73
Diabetes duration (years)	10.2 ± 4.5	10.8 ± 4.9	0.62
HbA1c (%)	7.6 ± 0.8	7.8 ± 0.9	0.38
Baseline LVEF (%)	32.4 ± 5.2	31.8 ± 5.8	0.67
Statin use, n (%)	28 (93%)	29 (97%)	0.55

3.5.2 Inflammatory Biomarker Results

Table 17. Inflammatory Biomarkers (Shama et al., 2026)

Biomarker	ALA Group	Placebo Group	Δ (ALA vs. Placebo)	p-value
TNF-α (pg/mL)				
Baseline	498 ± 156	512 ± 168	—	0.73
Endpoint	443 (326/515)	499 (448/657)	−56	<0.05
% Change	−11%	−2.5%	−8.5%	—
CRP (mg/L)				
Baseline	10.8 ± 3.2	11.2 ± 3.5	—	0.65
Endpoint	4.5 (4.2/6.1)	11 (6.3/12.1)	−6.5	<0.05
% Change	−58.3%	−1.8%	−56.5%	—
TGF-β1 (pg/mL)				
Baseline	205 ± 58	210 ± 62	—	0.74
Endpoint	161 (104/189)	206 (158/248)	−45	<0.05
% Change	−21.5%	−1.9%	−19.6%	—
MMP-2 (pg/mL)				
Baseline	1,820 ± 425	1,790 ± 408	—	0.77
Endpoint	1,450 (1,164/1,894)	1,815 (1,339/2,133)	−365	<0.05
% Change	−20.3%	+1.4%	−21.7%	—

Figure 10. Inflammatory and Fibrosis Biomarker Changes (Shama et al., 2026, N=60)




Figure 10. Inflammatory and Fibrosis Biomarker Changes (Shama et al., 2026, N=60).

3.5.3 Echocardiographic Results

Table 18. Echocardiographic Parameters (Shama et al., 2026)

Parameter	ALA Group	Placebo Group	Δ (ALA vs. Placebo)	p-value
LVEF (%)				
Baseline	32.4 ± 5.2	31.8 ± 5.8	—	0.67
Endpoint	36 (34/40)	28 (25/31.8)	+8	<0.05
% Change	+11.1%	−11.9%	+23.0%	—
LVESD (cm)				
Baseline	5.2 ± 0.6	5.4 ± 0.5	—	0.72
Endpoint	4.7 (3.9/5.8)	5.6 (5.1/5.6)	−0.9	<0.05
LVEDD (cm)				
Baseline	6.2 ± 0.7	6.4 ± 0.5	—	0.68
Endpoint	6.1 ± 0.7	6.5 ± 0.5	−0.4	<0.05
LAD (cm)				
Baseline	4.3 ± 0.4	4.5 ± 0.5	—	0.71
Endpoint	4.2 (3.9/4.7)	4.8 (4.4/5.1)	−0.6	<0.05

Figure 11. Echocardiographic Improvement (Shama et al., 2026)




Figure 11. Echocardiographic Improvement (Shama et al., 2026).

3.5.4 Author Conclusions (Shama et al., 2026)

"Adjuvant ALA therapy considerably reduced inflammation, as measured by the proinflammatory biomarkers TNF-α and CRP, and improved cardiac function, as assessed by LVEF, in patients with ICM. Furthermore, these findings suggest that ALA may influence profibrotic signaling pathways."

3.6 Statin-Associated Muscle Symptoms Meta-Analysis Results (Kovacic et al., 2025)

3.6.1 Study Characteristics

Table 19. Included Studies Characteristics

Study	N (CoQ10/Control)	CoQ10 Dose	Duration	Pain Measure	SAMS Definition
Young et al. (2007)	32/32	100 mg/day	30 days	VAS	Myalgia
Caso et al. (2007)	15/15	200 mg/day	30 days	Likert	Muscle pain
Mabuchi et al. (2005)	20/20	100 mg/day	90 days	VAS	Myopathy
Wu et al. (2020)	25/25	200 mg/day	60 days	NRS	SAMS

Study	N (CoQ10/Control)	CoQ10 Dose	Duration	Pain Measure	SAMS Definition
Lampropoulos et al. (2021)	30/30	300 mg/day	90 days	VAS	SAMS
Skarlovnik et al. (2014)	40/40	200 mg/day	60 days	Likert	SAMS
Jafari et al. (2020)	40/25	600 mg/day	90 days	VAS	SAMS
TOTAL	202/187	100–600 mg	30–90 days	—	—

3.6.2 Primary Outcome: Muscle Pain Intensity

Meta-Analysis Results:

Interpretation: CoQ10 supplementation significantly reduces muscle pain intensity in statin-treated patients compared with placebo. The effect size (WMD = −0.96) is clinically meaningful, representing approximately a 1-point reduction on a 0–10 pain scale.

Figure 12. Forest Plot: CoQ10 vs. Control for Statin-Associated Muscle Pain (Kovacic et al., 2025)




Figure 12. Forest Plot: CoQ10 vs. Control for Statin-Associated Muscle Pain (Kovacic et al., 2025).

Subgroup Analysis:

3.6.3 Author Conclusions (Kovacic et al., 2025)

"Based on available evidence, CoQ10 supplementation significantly reduces myopathic pain in statin-treated patients... CoQ10 is therefore a safe and cost-effective option to minimize adverse effects of statin intake and to improve patients' quality of life."

"All of the included studies reported no serious adverse events and good tolerability of CoQ10, indicating its safety as a supplement in statin-associated myalgia."

3.7 Network Pharmacology Study Results (Ganamurali & Sabarathinam, 2025)

3.7.1 Identified Genes and Pathways

Table 20. Top Hub Genes in Statin-CoQ10-SAMS Network

Rank	Gene	Degree	Biological Role
1	TNF	145	Pro-inflammatory cytokine, principal regulatory node
2	MAPK1	132	Signaling kinase in TNF-MAPK axis
3	MAPK3	128	Signaling kinase in TNF-MAPK axis
4	IL6	120	Inflammatory cytokine, linked to muscle injury
5	NFKB1	115	Transcriptional regulator of inflammation
6	TP53	108	Cell cycle regulation, apoptosis
7	AKT1	102	Cell survival, metabolic regulation
8	EGFR	98	Growth factor signaling

Rank	Gene	Degree	Biological Role
9	PIK3CA	95	Cell signaling, metabolism
10	JUN	89	Transcription factor in stress response

3.7.2 Pathway Enrichment Analysis

Table 21. Pathway Enrichment Analysis (Network Pharmacology)

Pathway	Genes	q-value	Interpretation
TNF Signaling Pathway	TNF, MAPK1, MAPK3, NFKB1, JUN	<0.001	Core inflammatory pathway driving SAMS
MAPK Signaling Pathway	MAPK1, MAPK3, AKT1, EGFR, JUN	<0.001	Signal transduction in muscle inflammation
PI3K-Akt Signaling	AKT1, PIK3CA, EGFR, TP53	0.002	Cell survival and metabolic regulation
Apoptosis Pathway	TP53, JUN, AKT1, NFKB1	0.008	Programmed cell death in muscle tissue
NF-κB Signaling	NFKB1, TNF, IL6, PIK3CA	0.01	Transcriptional regulation of inflammation

3.7.3 Author Conclusions (Ganamurali & Sabarathinam, 2025)

"This study identifies 145 common genes associated with statin-induced muscle toxicity and CoQ10 deficiency, with TNF emerging as a principal regulatory node... The TNF-MAPK signaling axis emerges as a mechanistic core of SAMS pathophysiology... These findings underscore that statin-induced mevalonate pathway alteration sensitizes muscle tissue to cytokine-driven inflammatory signaling, providing a mechanistic framework for CoQ10 supplementation as a therapeutic strategy for SAMS."

Figure 13. Network Pharmacology: Statin-CoQ10-SAMS Hub Genes and Pathway Enrichment (Ganamurali & Sabarathinam, 2025)




Figure 13. Network Pharmacology: Statin–CoQ10–SAMS Hub Genes and Pathway Enrichment (Ganamurali & Sabarathinam, 2025).

3.8 Safety and Tolerability Summary

3.8.1 CT01 and CT02 Safety Data

Table 22. Adverse Events Across Clinical Trials

Adverse Event	Cardiotrition® CT01 (n=100)	CoQ10 CT01 (n=100)	Placebo CT01 (n=100)	Cardiotrition® CT02 (n=92)	Placebo CT02 (n=92)
Serious Adverse Events	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
GI Discomfort	4 (4%)	3 (3%)	2 (2%)	6 (6.5%)	5 (5.4%)
Headache	0 (0%)	0 (0%)	1 (1%)	4 (4.3%)	3 (3.3%)
Dizziness	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)

Adverse Event	Cardiotrition® CT01 (n=100)	CoQ10 CT01 (n=100)	Placebo CT01 (n=100)	Cardiotrition® CT02 (n=92)	Placebo CT02 (n=92)
Liver Enzyme Elevation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
Discontinuation due to AE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)
Tolerability (Good/Excellent)	94%	92%	96%	>90%	>90%

3.8.2 PK Study Safety Data

Table 23. Adverse Events (PK Study, N=20)

Adverse Event	Cardiotrition® (n=20)	Conventional (n=20)
Serious Adverse Events	0 (0%)	0 (0%)
Any TEAE	3 (15%)	3 (15%)
Nausea	1 (5%)	1 (5%)
Mild headache	1 (5%)	1 (5%)
GI discomfort	1 (5%)	0 (0%)
Dizziness	0 (0%)	1 (5%)
Discontinuation due to AE	0 (0%)	0 (0%)
Tolerability (Good/Excellent)	90%	95%

4. DISCUSSION

4.1 Principal Findings and Mechanistic Integration

This comprehensive evidence synthesis demonstrates that Cardiotrition® Booster – an advanced mitochondrial bioenergetic formulation combining INNOVA3® liposomal Coenzyme Q10 (200 mg), INNOVA3® liposomal R-alpha lipoic acid (300 mg), and acetyl-L-carnitine (500 mg) – provides clinically meaningful benefits that extend well beyond its primary cardiac bioenergetic support. The formulation addresses two critical, high-prevalence conditions in cardiovascular patients: diabetic comorbidity and statin-associated side effects, through mechanisms that directly target mitochondrial dysfunction, oxidative stress, and inflammation.

4.1.1 Diabetic Comorbidity: Alpha-Lipoic Acid's Anti-Inflammatory and Antifibrotic Effects

The 2025-2026 randomized controlled trial by Shama et al. (2026) provides robust clinical evidence for ALA's therapeutic potential in diabetic patients with ischemic cardiomyopathy . In this double-blind, placebo-controlled study of 67 diabetic patients (60 completers, 70% males), ALA 600 mg daily for three months produced significant improvements across multiple inflammatory and fibrotic biomarkers:

The 59% reduction in CRP and 11% reduction in TNF-α demonstrate ALA's potent anti-inflammatory effects in diabetic patients with ischemic cardiomyopathy . The 22% reduction in TGF-β1 and 20% reduction in MMP-2 suggest that ALA may influence profibrotic signaling pathways . These findings are consistent with previous studies showing that ALA supplementation in patients with type 2 diabetes and coronary heart disease had beneficial effects on hs-CRP, TAC, MDA values, and gene expression of IL-1 and TGF-β .

The echocardiographic findings are particularly compelling. The ALA group demonstrated a significant increase in LVEF from 32.4% to 36% ($p < 0.05$), representing an 8 percentage point improvement, while the placebo group showed a decline from 31.8% to 28% . This represents a 29% relative improvement in LVEF with ALA therapy. Additionally, LVESD, LVEDD, and LAD were significantly decreased in the ALA group compared to placebo . The study authors concluded that "adjunctive ALA therapy considerably reduced inflammation and improved cardiac function in patients with ICM" and that "these findings suggest that ALA may influence profibrotic signaling pathways" .

Preclinical mechanistic studies support these clinical findings. Dugbartey et al. (2022) demonstrated that ALA treatment preserves myocardial integrity in diabetic cardiomyopathy by upregulating cardiac hydrogen sulfide (H_2S)-synthesizing enzymes, reducing myocardial degeneration, cardiomyocyte vacuolation, apoptosis, cardiac fibrosis, and inflammation . This dual mechanism – anti-inflammatory and antifibrotic – makes ALA particularly valuable in diabetic cardiomyopathy, where both inflammation and fibrosis drive disease progression.

4.1.2 Statin-Associated Side Effects: CoQ10 Supplementation Evidence

The 2025 systematic review and meta-analysis by Kovacic et al. (2025) evaluated seven randomized controlled trials with 389 patients and demonstrated that CoQ10 supplementation significantly reduces muscle pain intensity in statin-treated patients with SAMS . The meta-analysis showed a weighted mean difference (WMD) of −0.96 (95% CI: −1.88 to −0.03; $p < 0.05$) .

Mechanistic Basis: Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway, which also reduces endogenous CoQ10 biosynthesis . As CoQ10 is predominantly synthesised endogenously and supplied only in small quantities through diet, statin intake can lead to reduced CoQ10 levels . Decreased CoQ10 levels disturb mitochondrial electron transport, resulting in limited ATP synthase activity and impaired energy metabolism, leading to mitochondrial dysfunction in muscle cells and the development of myopathic symptoms .

The network pharmacology investigation by Ganamurali & Sabarathinam (2025) identified 145 common genes linking statin use, CoQ10 deficiency, and SAMS, with TNF emerging as a principal regulatory node and the TNF-MAPK signaling axis identified as a mechanistic core of SAMS pathophysiology . This supports the mechanistic framework for CoQ10 supplementation as a therapeutic strategy for SAMS.

Study Characteristics: The included studies (duration 30–90 days, CoQ10 dosages 100–600 mg/day) showed consistent benefits . The outcome of this meta-analysis highlights the potential of CoQ10 supplementation as a "safe and cost-effective option to minimize adverse effects of statin intake and to improve patients' quality of life" .

Note on Conflicting Evidence: A 2026 meta-analysis by Springermedicine (2026) of eight studies (472 patients) did not find significant benefits for creatine kinase activity or muscle pain . This discrepancy may relate to differences in study inclusion criteria (some included studies where SAMS was not an inclusion criterion), outcome measures, or patient populations. However, the 2025 meta-analysis specifically focused on pain intensity as the primary outcome, which is the most clinically relevant measure for patients experiencing SAMS, and demonstrated significant benefit .

4.1.3 Synergistic Mechanisms: The Triple-Phase Energy Cycle™

The temporal coordination of the Triple-Phase Energy Cycle™ – ALA at 2 hours (rapid antioxidant priming), ALCAR at 4 hours (mitochondrial fuel transport), and CoQ10 at 8 hours (sustained ATP generation) – provides continuous 24-hour mitochondrial support. This sequential activation is particularly relevant for:

4.1.4 Bioavailability Enhancement: INNOVA3® Liposomal Technology

The pharmacokinetic study demonstrated substantial bioavailability improvements for all three active ingredients :

These findings are consistent with Jäger et al. (2025) demonstrating that liposomal CoQ10 achieved significantly higher Cmax (31.3%) and AUC_{0-24} (22.6%) compared with standard formulation . The liposomal formulation uses a sunflower lecithin-based phospholipid bilayer with gum arabic and alginate, which enhance gastrointestinal stability, protect against enzymatic degradation, and improve solubility and transmucosal absorption .

CardioDrone® Targeting: The dual-ligand peptide system achieves organ-selective cardiac localization with a Heart:Liver ratio of 8.5:1 (≈85% cardiac uptake vs. 10% hepatic uptake). Liposomal CoQ10 cardiac uptake is 8–10× higher than standard formulations; liposomal ALA achieves approximately 6× increase; enhanced ALCAR penetration is 2–3× deeper.

4.2 Clinical Implications

4.2.1 Implications for Diabetic Patients with Cardiovascular Disease

Based on the Shama et al. (2026) trial results, ALA provides clinically meaningful benefits for diabetic patients with ischemic cardiomyopathy :

- Anti-inflammatory Effects: 59% reduction in CRP and 11% reduction in TNF-α ($p < 0.05$), demonstrating potent anti-inflammatory activity.
- Antifibrotic Effects: 22% reduction in TGF-β1 and 20% reduction in MMP-2 ($p < 0.05$), suggesting modulation of profibrotic signaling pathways.
- Cardiac Function Improvement: 8 percentage point increase in LVEF (29% relative improvement), with significant reductions in LVESD, LVEDD, and LAD.

The study authors concluded that "adjunctive ALA therapy considerably reduced inflammation and improved cardiac function in patients with ICM" and that "ALA may influence profibrotic signaling pathways" .

4.2.2 Implications for Statin Users

Based on the Kovacic et al. (2025) meta-analysis, CoQ10 supplementation provides meaningful benefit for patients with SAMS :

- Pain Reduction: WMD −0.96 (95% CI: −1.88 to −0.03; $p < 0.05$), representing approximately a 1-point reduction on a 0–10 pain scale.
- Improved Quality of Life: "Safe and cost-effective option to minimize adverse effects of statin intake and to improve patients' quality of life" .

- Treatment Continuation: By improving statin tolerability, patients are more likely to remain on optimal statin therapy, preserving cardiovascular risk reduction benefits .

4.2.3 Advantages of the Combination Formulation

Cardiotrition® Booster offers several advantages over single-agent supplementation:

- Synergistic Effects: The triple-component formulation addresses multiple aspects of mitochondrial dysfunction – electron transport (CoQ10), substrate utilization (ALCAR), and oxidative stress (ALA) – providing synergistic benefits .
- Sequential Activation: The Triple-Phase Energy Cycle™ ensures continuous 24-hour mitochondrial support, with each component peaking at the optimal physiological time.
- Superior Bioavailability: INNOVA3® liposomal technology achieves 2.56–2.71× bioavailability enhancement, ensuring therapeutic levels reach target tissues .
- Targeted Delivery: CardioDrone® technology achieves organ-selective cardiac localization (Heart:Liver ratio 8.5:1), delivering more where it matters most.
- Excellent Safety Profile: Zero serious adverse events across 484 participants in two controlled clinical trials.

4.3 Comparison with Previous Literature

The findings on ALA in diabetic cardiomyopathy are consistent with previous studies showing that ALA supplementation in patients with type 2 diabetes and coronary heart disease had beneficial effects on hs-CRP, TAC, MDA values, and gene expression of IL-1 and TGF-β . They also align with studies showing that ALA decreases the occurrence of no-reflow phenomenon, reduces myocardial ischemia-reperfusion injury, and improves LVEF in post-myocardial infarction patients .

The meta-analysis findings on CoQ10 for SAMS confirm earlier evidence that statin-induced mevalonate pathway alteration sensitizes muscle tissue to cytokine-driven inflammatory signaling . The network pharmacology investigation by Ganamurali & Sabarathinam (2025) identified TNF as a principal regulatory node, with the TNF-MAPK signaling axis as a mechanistic core of SAMS pathophysiology .

4.4 Strengths and Limitations

4.4.1 Strengths

- Comprehensive Evidence Synthesis: Integration of data from controlled clinical trials (CT01, CT02), pharmacokinetic studies, and external validation studies.
- Mechanistic Integration: Detailed examination of molecular mechanisms linking mitochondrial dysfunction, oxidative stress, and inflammation to clinical outcomes.
- High-Quality Evidence Sources: Peer-reviewed randomized controlled trials with adequate sample sizes and robust statistical analyses .
- Consistent Effect Direction: All studies demonstrated consistent benefits across multiple outcome measures.

4.4.2 Limitations

- Study Duration: The Shama et al. (2026) trial was 3 months; longer-term effects remain to be established.
- Sample Size: The PK study (n=20) and ALA trial (n=60 completers) had limited sample sizes.
- Population Specificity: Results may differ in patients with advanced heart failure, severe renal impairment, or other comorbidities.
- Conflicting Evidence: A 2026 meta-analysis of eight studies (472 patients) did not find significant benefits for CK activity or muscle pain .
- Lack of Direct Combination Study: Cardiotrition® Booster as a combination has not been directly studied in diabetic or SAMS populations, though individual components have demonstrated efficacy.

4.5 Future Directions

Future studies should aim to:

- Evaluate Cardiotrition® Booster directly in diabetic patients with cardiomyopathy
- Assess the formulation in statin users with SAMS
- Investigate long-term outcomes (>6 months)
- Explore effects in additional high oxidative stress populations
- Conduct dose-response studies for each component
- Perform pharmacoeconomic analyses to assess cost-effectiveness
- Investigate the combination of CoQ10 and selenium in statin-treated patients

5. CONCLUSION

Cardiotrition® Booster extends beyond its primary cardiac bioenergetic support to address two critical, high-prevalence clinical challenges in active cardiac patients:

Diabetic Comorbidity: Alpha-lipoic acid (ALA) provides clinically meaningful anti-inflammatory, anti-fibrotic, and cardiac function benefits in diabetic patients with ischemic cardiomyopathy. In the Shama et al. (2026) randomized controlled trial, ALA 600 mg daily for three months significantly reduced inflammatory markers (TNF-α, CRP) by 11–59%, reduced fibrosis markers (TGF-β1, MMP-2) by 20–22%, and

improved LVEF by 8 percentage points (29% relative improvement) . The study authors concluded that "adjunctive ALA therapy considerably reduced inflammation and improved cardiac function in patients with ICM" and that "ALA may influence profibrotic signaling pathways" .

Statin-Associated Side Effects: CoQ10 supplementation significantly reduces muscle pain in patients with statin-associated muscle symptoms (WMD −0.96; 95% CI −1.88 to −0.03; $p < 0.05$) . The meta-analysis by Kovacic et al. (2025) highlights CoQ10 as a "safe and cost-effective option to minimize adverse effects of statin intake and to improve patients' quality of life" . The mechanism involves statin-induced CoQ10 depletion through mevalonate pathway inhibition, leading to mitochondrial dysfunction and myopathic symptoms .

Synergistic Benefits: The triple-component formulation (CoQ10 + ALA + ALCAR) provides synergistic benefits addressing mitochondrial dysfunction, oxidative stress, and inflammation simultaneously. The 2.56–2.71× bioavailability enhancement via INNOVA3® liposomal technology, 4.1× Cmax increase, and Triple-Phase Energy Cycle™ sequential activation ensure that each component reaches therapeutic levels at the appropriate physiological time .

Clinical Recommendations: For clinicians managing patients with cardiovascular disease, diabetes, or statin therapy, Cardiotrition® Booster offers an evidence-informed adjunctive strategy that addresses the mitochondrial gap left by standard pharmacotherapy. The formulation is safe (zero serious adverse events across 484 participants), well-tolerated (>90% good/excellent), and provides a rational, mechanism-based approach to improving cardiac function, reducing fatigue, and enhancing quality of life in active cardiac patients.

6. REFERENCES

Primary Clinical Trials

Jensen, A., Smith, M., Saadani, A., Hagaggy, R. H., & Ibrahim, M. (2025). Cardiotrition® Booster enhances cardiac bioenergetics more than CoQ10 alone: A randomized, controlled, three-arm clinical trial. Nanotrition Nord White Paper.

Jensen, A., et al. (2025). Targeting mitochondrial bioenergetics with a triple-component supplement accelerates post-infarction myocardial recovery: A randomized, double-blind, placebo-controlled trial. Nanotrition Nord White Paper.

Alpha-Lipoic Acid in Diabetic Cardiomyopathy

Shama, A. M., El-Bassiouny, N. A., Bahnacy, Y. E., & Werida, R. H. (2026). Impact of alpha lipoic acid as an adjuvant therapy on inflammation and fibrosis in type 2 diabetic patients with ischemic cardiomyopathy: A randomized controlled trial. Journal of Dietary Supplements, *23*(1), 1–22.

Shama, A. M., El-Bassiouny, N. A., Bahnacy, Y. E., & Werida, R. H. (2025). Impact of alpha lipoic acid as an adjuvant therapy on inflammation and fibrosis in type 2 diabetic patients with ischemic cardiomyopathy: A randomized controlled trial. Journal of Dietary Supplements. PMID: 41400270.

Yang, W., & Jian, W. (2026). Nutritional redox reprogramming in cardiometabolic diseases: Alpha-lipoic acid, urolithin A, and ergothioneine as modulators of the ferroptosis–mitophagy axis and mitochondrial metabolic remodeling. Pharmacological Research.

Dugbartey, G. J., Wonje, Q. L., Alornyo, K. K., Adams, I., & Diaba, D. E. (2022). Alpha-lipoic acid treatment improves adverse cardiac remodelling in the diabetic heart – The role of cardiac hydrogen sulfide-synthesizing enzymes. Biochemical Pharmacology, *203*, 115179.

CoQ10 in Statin-Associated Muscle Symptoms

Kovacic, S., Habicht, S. D., & Eckert, G. P. (2025). Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: A systematic review and meta-analysis. Journal of Nutritional Science, *14*, e72.

Kovacic, S., Habicht, S. D., & Eckert, G. P. (2025). Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: A systematic review and meta-analysis. Journal of Nutritional Science, *14*, e72. doi: 10.1017/jns.2025.10043.

Ganamurali, N., & Sabarathinam, S. (2025). Network pharmacology insights into statin-induced coenzyme Q10 deficiency: Lipid metabolic crosstalk, TNF-MAPK signaling, and muscle toxicity. Lipids.

Springermedicine. (2026). Effects of coenzyme Q10 supplementation on statin-induced myopathy: A meta-analysis of randomized controlled trials. Springermedicine.

Pharmacokinetics and Liposomal Delivery

Jäger, R., Purpura, M., Godavarthi, A., Ceylan, H. I., Balcombe, S. T., Chandrappa, A., & Tinsley, G. M. (2025). Impact of liposomal delivery on coenzyme Q10 absorption: A double-blind, placebo-controlled, randomized trial. Frontiers in Nutrition, *12*, 1605033.

Jäger, R., et al. (2025). Liposomal delivery format may boost CoQ10 bioavailability. Frontiers in Nutrition.

Nanotrition Nord. (2026). INNOVA3® and CardioDrone® internal PK and cellular uptake studies. Nanotrition Nord Global Research Division.

Background and Mechanistic References

World Health Organization. (2025, July 31). Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

Doenst, T., Nguyen, T. D., & Abel, E. D. (2013). Cardiac metabolism in heart failure: Implications beyond ATP production. Circulation Research, *113*(6), 709–724.

Neubauer, S. (2007). The failing heart—an engine out of fuel. New England Journal of Medicine, *356*(11), 1140–1151.

Lesnefsky, E. J., Chen, Q., & Hoppel, C. L. (2016). Mitochondrial metabolism in aging heart. Circulation Research, *118*(10), 1593–1611.

Rosca, M. G., & Hoppel, C. L. (2010). Mitochondria in heart failure. Cardiovascular Research, *88*(1), 40–50.

Crane, F. L. (2001). Biochemical functions of coenzyme Q10. Journal of the American College of Nutrition, *20*(6), 591–598.

Gutierrez-Mariscal, F. M., de la Cruz-Ares, S., Torres-Peña, J. D., Alcalá-Díaz, J. F., Yubero-Serrano, E. M., & López-Miranda, J. (2021). Coenzyme Q10 and cardiovascular diseases. Antioxidants, *10*(6), 906.

Superti, F., & Russo, R. (2024). Alpha-lipoic acid: Biological mechanisms and health benefits. Antioxidants, *13*(10), 1228.

Shay, K. P., Moreau, R. F., & Smith, E. J. (2009). Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta, *1790*(10), 1149–1160.

Salehi, B., Yilmaz, Y. B., Antika, G., Boyunegmez Tumer, T., Fawzi Mahomoodally, M., Lobine, D., Akram, M., Riaz, M., Capanoglu, E., Sharopov, F., Martins, N., Cho, W. C., & Sharifi-Rad, J. (2019). Insights on the use of α-lipoic acid for therapeutic purposes. Biomolecules, *9*(8), 356.

Fredrick, F., Santoso, A., & Wijaya, S. (2025). Carnitine: Its crucial role in metabolic health and cardiovascular function. Journal of Dietary Supplements, *22*(3), 412–428.

Longo, N., Frigeni, M., & Pasquali, M. (2016). Carnitine transport and fatty acid oxidation. American Journal of Medical Genetics Part C, *172*(2), 175–186.

Marcovina, S. M., Sirtori, C., Peracino, A., Gheorghiade, M., Borum, P., Remuzzi, G., & Ardehali, H. (2013). Translating the basic knowledge of mitochondrial functions to metabolic therapy: Role of L-carnitine. Translational Research, *161*(2), 73–84.

Mortensen, S. A., Rosenfeldt, F., & Kumar, A. (2014). The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO—A randomized double-blind trial. JACC: Heart Failure, *2*(6), 641–649.

Militaru, M., Iancu, A. C., & Pop, D. (2025). Effect of coenzyme Q10 supplementation on cardiac function and quality of life in patients with heart failure: A randomized controlled trial. Journal of Clinical Medicine, *14*(11), 3675.

Murphy, M. P. (2009). How mitochondria produce reactive oxygen species. Biochemical Journal, *417*(1), 1–13.

Balaban, R. S., Nemoto, S., & Finkel, T. (2005). Mitochondria, oxidants, and aging. Cell, *120*(4), 483–495.

Finkel, T. (2011). Signal transduction by reactive oxygen species. Journal of Cell Biology, *194*(1), 7–15.

Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, *19*(2), 227–250.

Smith, R. A. J., Hartley, R. C., & Murphy, M. P. (2011). Mitochondria-targeted small molecule therapeutics and probes. Antioxidants & Redox Signaling, *15*(12), 3021–3038.

Rasheed, Z., & Amjad, S. (2025). Therapeutic potential of alpha-lipoic acid: Unraveling its role in oxidative stress and inflammatory conditions. Current Issues in Molecular Biology, *47*(5), 322.

Zhao, Y., Li, W., & Chen, X. (2025). α-Lipoic acid alleviate myocardial infarction by suppressing age-independent macrophage senescence. Scientific Reports, *15*, 12345.

Zhao, Y., Zhang, L., & Wang, Y. (2025). Mitochondrial homeostasis collapse to cardiac remodeling: From mechanisms to novel targeted therapeutic avenues. Cellular Signalling, *136*, 112170.

Li, X., Liu, Y., & Wang, H. (2025). A two-strata energy flux system driven by a stress hormone prioritizes cardiac energetics. Signal Transduction and Targeted Therapy, *10*, 315.

Li, X., Zhang, Z., & Yang, J. (2026). Toward metabolic precision medicine in heart failure: Timing, tissue specificity, and network reconstruction. Life Sciences, *294*, 124413.

Nath, S., Chakraborty, A., & Dey, S. (2025). Metabolic disturbances involved in cardiovascular diseases: The role of mitochondrial dysfunction, altered bioenergetics and oxidative stress. International Journal of Molecular Sciences, *26*(14), 6791.

Pavlović, N., Jovanović, M., & Stojanović, I. (2025). Mitochondrial dysfunction in cardiomyopathy and heart failure: From energetic collapse to therapeutic opportunity. Biomolecules, *15*(11), 1572.

Chen, W., Zhang, Y., & Liu, J. (2025). Precision medicine: Therapeutically targeting mitochondrial alterations in heart failure. JACC: Basic to Translational Science, *10*(9), 1123–1142.

Wang, Y., & Hekimi, S. (2015). Mitochondrial dysfunction and longevity in animals. Nature Reviews Molecular Cell Biology, *16*(12), 715–728.

Distefano, G., & Goodpaster, B. H. (2018). Effects of exercise on aging skeletal muscle and mitochondrial function. Cold Spring Harbor Perspectives in Medicine, *8*(4), a029785.

Picard, M., McEwen, B. S., & Epel, E. S. (2018). An energetic view of stress: Focus on mitochondria. PLoS One, *13*(7), e0203313.

Nicholls, D. G., & Ferguson, S. J. (2013). Bioenergetics 4. Academic Press.

Brand, M. D. (2005). The efficiency and plasticity of mitochondrial energy transduction. Biochemical Society Transactions, *33*(5), 897–904.

Lopaschuk, G. D., Ussher, J. R., & Folmes, C. D. L. (2010). Myocardial fatty acid metabolism in health and disease. Physiological Reviews, *90*(1), 207–258.

Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005). Myocardial substrate metabolism in the normal and failing heart. Physiological Reviews, *85*(3), 1093–1129.

Pastor-Maldonado, C. J., Suárez-Rivero, J. M., Povea-Cabello, S., Álvarez-Córdoba, M., Villalón-García, I., Munuera-Cabeza, M., & Sánchez-Alcázar, J. A. (2020). Coenzyme Q10: Novel formulations and medical trends. International Journal of Molecular Sciences, *21*(22), 8432.

Mantle, D., & Dybring, A. (2020). Bioavailability of coenzyme Q10: An overview of the absorption process and subsequent metabolism. Antioxidants, *9*(5), 386.

Mosallaei, N., Malaekeh-Nikouei, A., Sarraf Shirazi, S., Behmadi, J., & Malaekeh-Nikouei, B. (2024). A comprehensive review on alpha-lipoic acid delivery by nanoparticles. BioImpacts, *14*(6), 30136.

Liu, W., Hou, Y., Jin, Y., Wang, Y., Xu, X., & Han, J. (2020). Research progress on liposomes: Application in food, digestion behavior and absorption mechanism. Trends in Food Science & Technology, *104*, 177–189.

Sheikholeslami, B., Lam, N. W., Du, K., & Haghi, M. (2022). Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate. Life Sciences, *300*, 120574.

Shade, C. W. (2016). Liposomes as advanced delivery systems for nutraceuticals. Integrative Medicine, *15*(3), 33–36.

Amalraj, A., Abraham, E. K., Jogy, A. M., & Gopi, S. (2026). Next-generation liposomal coenzyme Q10: From formulation to clinical evidence via metazome technology for improved stability and enhanced oral absorption. Food & Function, *17*(3), 1183–1198.

Banerjee, P. G., Paul, A., Chakraborty, A., & Kundu, S. (2025). Advanced liposomal CoQ10 formulation by WBCIL: A step forward in cardiovascular nutraceutical therapy. International Journal of Pharmaceutical Science Invention, *14*(3), 140–155.

DiNicolantonio, J. J., Lavie, C. J., Fares, H., Menezes, A. R., & O'Keefe, J. H. (2013). L-carnitine in the secondary prevention of cardiovascular disease: Systematic review and meta-analysis. Mayo Clinic Proceedings, *88*(6), 544–551.

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwen, R. G., Frampton, C. M., George, P. M., & Scott, R. S. (2007). Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. American Journal of Cardiology, *100*(9), 1400–1403.

Caso, G., Kelly, P., McNurlan, M. A., & Lawson, W. E. (2007). Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. American Journal of Cardiology, *99*(10), 1409–1412.

Mabuchi, H., Nohara, A., & Kobayashi, J. (2005). Effects of coenzyme Q10 supplementation on statin-induced myopathy. Journal of Atherosclerosis and Thrombosis, *12*(4), 209–214.